Cangrelor Infusion for Coronary Arterial Disease
The Bridging Antiplatelet Therapy With Cangrelor 2 Study
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 50 (estimated)
- Sponsor
- University of Florida · Other
This trial is looking for patients with coronary arterial disease who are currently receiving a specific dose of cangrelor treatment. Taking part involves being monitored for how well your platelets are reacting to the medication.
You may be able to join if
- I am at least 18 years old
- I have been receiving cangrelor treatment for at least two hours
- I can provide written consent to participate
You may not be able to join if
- I need urgent surgery
- I am pregnant or breastfeeding
- I have taken certain blood thinners in the last 48 hours
- I am allergic to cangrelor or related medications
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThe primary aim of this study is to determine rates of patients with optimal platelet reactivity range, defined as PRU levels between 85 and 208, when using a (PFT)-guided titration of cangrelor infusion rate (cangrelor titration) compared to 0.75 mcg/kg/min (standard-dose infusion) for bridging.
Loading trial locations…